Britain approves Merck's oral Covid-19 pill
The Medicines and Healthcare products Regulatory Agency recommended that the drug be used as soon as possible following a positive Covid-19 test and within five days of the onset of symptoms.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS
Britain on Thursday became the first country in the world to approve a potentially game-changing Covid-19 antiviral oral pill jointly developed by Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.
The Medicines and Healthcare products Regulatory Agency (MHRA) recommended that the drug, molnupiravir, be used as soon as possible following a positive Covid-19 test and within five days of the onset of symptoms.
The government and the NHS will confirm how this Covid-19 treatment will be deployed to patients in due course.
Keep updated, follow The Business Standard's Google news channel
Separately, Merck said it was expecting to produce 10 million courses of the treatment by the end of this year, with at least 20 million courses set to be manufactured in 2022.
